GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. specialty division ofIntas Pharmaceuticals, Ltd.(&qu...
View DetailsGuangzhou and London – May 22, 2025) Injection, a biosimilarreferencing Stelara® (ustekinumab) Injection. STARJEMZA® is Bio-Thera’s third FDA approved product. “The approval of STARJEMZA® is another significantaccomplishment for Bio-Thera, establishi...
Guangzhou, China– April 14, 2025 –Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, will have anoral presentation in collaboration with medical centers at ...
Guangzhou, China/ Hyderabad, India – March 26,2025 – Bio-Thera Solutions (688177:SH; “Bio-Thera”), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies andbiosimilars, and Dr. Reddy’s Laboratories SA, wholly-owned...
